SCHEMBL1199002

SCHEMBL1199002

Cc1sc(-c2cc(Br)cc(C(F)(F)F)c2)nc1CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
RORB Q92753 3/20 0.39
RORC P51449 2/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NOTUM Q6P988 1/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
DCK P27707 2/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
ACP1 P24666 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876031 0.82 DCK (0.36) KDM4EGAADCKPPARGPPARA
SCHEMBL1199289 0.80 ALDH1A1 (0.56) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL5102703 0.79 MAPT (0.52) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL1197887 0.76 KMT2A (0.52) MEN1MAPTKMT2ARORBRORC
SCHEMBL1199073 0.76 EGLN1 (0.38) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL1197708 0.74 PPARG (0.34) RORBRORCS1PR1S1PR3NPC1
SCHEMBL18004069 0.74 DCK (0.57) DCKPPARGPPARA
SCHEMBL1199152 0.73 MAPT (0.44) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL9628640 0.71 MEN1 (0.45) MEN1MAPTKMT2A
SCHEMBL4472919 0.71 ALDH1A1 (0.45) MEN1MAPTKMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885MAPT 4667/4885KMT2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.